Content area
Full Text
Industry: MEDICAL/PHARMACEUTICALS
NATICK, Mass., Nov. 3 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today that in connection with certain routine internal review, analysis and audit procedures, it has detected the occurrence of business irregularities in the operations of its Japanese subsidiary. The irregularities detected involve shipments of products that have been improperly recorded as sales to the subsidiary's dealer network in Japan. Based on preliminary information, the magnitude...